<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03453931</url>
  </required_header>
  <id_info>
    <org_study_id>P2017/556 / B406201734265</org_study_id>
    <nct_id>NCT03453931</nct_id>
  </id_info>
  <brief_title>Arrhythmias, Microalbuminuria and Corticosteroids</brief_title>
  <official_title>Arrhythmias, Heart Rate Variability and Microalbuminuria After Intravenous Corticosteroids: An Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elza ABDESSATER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université Libre de Bruxelles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this observational design is to study the effects of intravenous corticosteroids
      on heart rate variability, arrhythmias and microalbuminuria. Some previous studies have shown
      that intravenous corticosteroids could induce bradycardia but also supra-ventricular
      tachycardia and atrial fibrillation.

      A second goal of this study is to investigate whether exogenous corticosteroids may induce
      microalbuminuria. A large retrospective study has revealed an association between
      microalbuminuria and corticosteroid use in the year preceding the measurement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      On intra-hospital patients, it will be explored the prevalence of arrythmias, the heart rate
      variability and the modification of the microalbuminuria level after intravenous infusion of
      corticosteroids. The investigator shall not initiate the treatment. Patients will receive
      high-dose intravenous corticosteroids for the treatment of different diseases. The
      departments, where the patients are enrolled, are: nephrology, neurology, dermatology and
      rheumatology and the day hospital. The day before the corticosteroids administration, a
      holter monitor will be started for at least 24h to detect arrhythmias and heart rate
      variations. By mean of a Finometer, beat-to-beat blood pressure, cardiac output and
      baroreflex sensitivity will be measured before, during and after the infusion. Blood and
      urine samples will be used to explore the effects of corticosteroids on microalbuminuria,
      electrolytes, CRP and glomerular filtration rate during the 3 days of observation.

      To our knowledge, it will be the first prospective trial to explore a link between
      intravenous corticosteroids administration and heart rate variability, Baroreflex
      Sensitivity, as well as microalbuminuria.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Arrhythmias</measure>
    <time_frame>Change between day 1 and day 3</time_frame>
    <description>All types of arrhythmias (especially pauses and atrial fibrillation). Evaluated with a 72-hours Holter ECG monitoring</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microalbuminuria</measure>
    <time_frame>Change in microalbuminuria (day 1 and day 3)</time_frame>
    <description>Microalbuminuria (mg/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microalbuminuria - Urinary Creatinine ratio</measure>
    <time_frame>Change in microalbuminuria - urinary creatinine ratio (day 1 and day 3)</time_frame>
    <description>mg/g creatinine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baroreflex Sensitivity</measure>
    <time_frame>Change in Baroreflex Sensitivity (day 1 and day 3)</time_frame>
    <description>Measured with a Finometer (ms/mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beat-to-beat blood pressure</measure>
    <time_frame>Change in beat-to-beat blood pressure (day 1 and day 3)</time_frame>
    <description>Measured with a Finometer (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>Change in Heart Rate (day 1 and day 3)</time_frame>
    <description>Measured with a 72 hours Holter ECG monitoring (bpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard Deviation of normal to normal R-R intervals (SDNN)</measure>
    <time_frame>Change in SDNN (day 1 and day 3)</time_frame>
    <description>Measured with a 72 hours Holter ECG monitoring (ms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Root Mean Square of the Successive Differences (RMSSD)</measure>
    <time_frame>Change in RMSSD (day 1 and day 3)</time_frame>
    <description>Measured with a 72 hours Holter ECG monitoring (ms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of times per hour in which the change in consecutive normal sinus R-R intervals exceeds 50 milliseconds (PNN50)</measure>
    <time_frame>Change in PNN50 (day 1 and day 3)</time_frame>
    <description>Measured with a 72 hours Holter ECG monitoring (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Frequency component of Heart Rate Variability (LF)</measure>
    <time_frame>Change in low frequencies (day 1 and day 3)</time_frame>
    <description>Measured with a 72 hours Holter ECG monitoring (ms^2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Frequency component of Heart Rate Variability (HF)</measure>
    <time_frame>Change in high frequencies (day 1 and day 3)</time_frame>
    <description>Measured with a 72 hours Holter ECG monitoring (ms^2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low to High Frequency Ratio of Heart Rate Variability (LF/HF)</measure>
    <time_frame>Change in LF/HF (day 1 and day 3)</time_frame>
    <description>Measured with a 72 hours Holter ECG monitoring</description>
  </secondary_outcome>
  <other_outcome>
    <measure>CRP</measure>
    <time_frame>before and 1 to 3 days after the drug infusion</time_frame>
    <description>(mg/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Glomerular Filtration Rate</measure>
    <time_frame>Before and 1 to 3 days after the drug infusion</time_frame>
    <description>CKD-EPI (mL/min/1.73m2)</description>
  </other_outcome>
  <other_outcome>
    <measure>Natremia</measure>
    <time_frame>Change in Natremia (day 1 and day 3)</time_frame>
    <description>mmol/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Kaliemia</measure>
    <time_frame>Change in Kaliemia (day 1 and day 3)</time_frame>
    <description>mmol/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Chloremia</measure>
    <time_frame>Change in Chloremia (day 1 and day 3)</time_frame>
    <description>mmol/L</description>
  </other_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Corticosteroids Adverse Reaction</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroid injection</intervention_name>
    <description>Intravenous high dose corticosteroids</description>
    <other_name>Solumedrol</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized patients who are starting high-dose corticotherapy in Hôpital Erasme
        (Brussels).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Starting high-dose intravenous corticotherapy

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Marc Leeman, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Université Libre de Bruxelles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elza Abdessater</last_name>
    <phone>0474385386</phone>
    <email>eabdessa@ulb.ac.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Benjamin De Becker, MD</last_name>
    <email>bendebec@ulb.ac.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Erasme hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elza Abdessater</last_name>
      <phone>0474385386</phone>
      <email>eabdessa@ulb.ac.be</email>
    </contact>
    <contact_backup>
      <last_name>Benjamin De Becker</last_name>
      <email>bendebec@ulb.ac.be</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2018</study_first_submitted>
  <study_first_submitted_qc>February 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2018</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Université Libre de Bruxelles</investigator_affiliation>
    <investigator_full_name>Elza ABDESSATER</investigator_full_name>
    <investigator_title>Medical Student (Master 4)</investigator_title>
  </responsible_party>
  <keyword>Corticosteroids</keyword>
  <keyword>Arrhythmia</keyword>
  <keyword>Heart Rate Variability</keyword>
  <keyword>Albuminuria</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

